ASTRAZEN — Astrazeneca Pharma India Share Price
0.000.00%
Last trade - 00:00- IN₹185.92bn
- IN₹180.91bn
- IN₹12.96bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 26.11 | ||
| Price to Tang. Book | 26.19 | ||
| Price to Free Cashflow | 1,086.6 | ||
| Price to Sales | 13.4 | ||
| EV to EBITDA | 158.49 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 13.75% | ||
| Return on Equity | 14.74% | ||
| Operating Margin | 7.14% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 8,318.1 | 8,135.6 | 8,056 | 10,029.7 | 12,955.3 | n/a | n/a | 12.21% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +32.39 | +27.32 | -35.11 | +113.81 | +18.14 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; oncology, and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacturing, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
Directors
- Darius Udwadia NEC (82)
- Rajesh Marwaha CFO (54)
- Pratap Rudra CCO
- Gagan Bedi MDR (49)
- Sanjay Murdeshwar MDR (48)
- Gagandeep Singh MDR
- Claire-Marie O'Grady DRC
- Ian Brimicombe NED (51)
- Ankush Nandra NED
- Ian Parish NED (45)
- Weiying Sarah Wang NED
- Narayan Seshadri NED (58)
- Revathy Ashok NID (62)
- Shilpa Divekar NID
- K. Shah NID (74)
- Last Annual
- March 31st, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- July 11th, 1979
- Public Since
- July 30th, 1998
- No. of Shareholders
- 29,418
- No. of Employees
- 940
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 25,000,000
- Address
- Ni 12Th Floor, Manyata Empassy Business, BANGALORE, 560045
- Web
- https://www.astrazeneca.in/
- Phone
- +91 8067748000
- Auditors
- price waterhouse & co chartered accountants llp
Upcoming Events for ASTRAZEN
Q3 2025 Astrazeneca Pharma India Ltd Earnings Release
Similar to ASTRAZEN
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Astrazeneca Pharma India share price?
As of Today at 19:24 UTC, shares in Astrazeneca Pharma India are trading at IN₹7,436.70. This share price information is delayed by 15 minutes.
How has the Astrazeneca Pharma India share price performed this year?
Shares in Astrazeneca Pharma India last closed at IN₹7,436.70 and the price had moved by +65.11% over the past 365 days. In terms of relative price strength the Astrazeneca Pharma India share price has outperformed the S&P BSE 100 Index by +24.82% over the past year.
What are the analyst and broker recommendations for Astrazeneca Pharma India?
The overall consensus recommendation for Astrazeneca Pharma India is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Astrazeneca Pharma India dividend yield?
The Astrazeneca Pharma India dividend yield is 0.32% based on the trailing twelve month period.
Does Astrazeneca Pharma India pay a dividend?
Last year, Astrazeneca Pharma India paid a total dividend of IN₹24.00, and it currently has a trailing dividend yield of 0.32%. We do not have any data on when Astrazeneca Pharma India is to next pay dividends.
When does Astrazeneca Pharma India next pay dividends?
We do not have data on when Astrazeneca Pharma India is to next pay dividends. The historic dividend yield on Astrazeneca Pharma India shares is currently 0.32%.
How do I buy Astrazeneca Pharma India shares?
To buy shares in Astrazeneca Pharma India you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Astrazeneca Pharma India?
As of the previous close price of IN₹7,436.70, shares in Astrazeneca Pharma India had a market capitalisation of IN₹185.92bn.
Where are Astrazeneca Pharma India shares listed?
Here are the trading details for Astrazeneca Pharma India:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: ASTRAZEN
What kind of share is Astrazeneca Pharma India?
Based on an overall assessment of its quality, value and momentum Astrazeneca Pharma India is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Astrazeneca Pharma India share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Astrazeneca Pharma India share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Astrazeneca Pharma India. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +29.35%.
As of the last closing price of IN₹7,436.70, shares in Astrazeneca Pharma India were trading +22.12% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Astrazeneca Pharma India PE Ratio?
The Astrazeneca Pharma India PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹7,436.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Astrazeneca Pharma India?
Astrazeneca Pharma India's management team is headed by:
- Darius Udwadia - NEC
- Rajesh Marwaha - CFO
- Pratap Rudra - CCO
- Gagan Bedi - MDR
- Sanjay Murdeshwar - MDR
- Gagandeep Singh - MDR
- Claire-Marie O'Grady - DRC
- Ian Brimicombe - NED
- Ankush Nandra - NED
- Ian Parish - NED
- Weiying Sarah Wang - NED
- Narayan Seshadri - NED
- Revathy Ashok - NID
- Shilpa Divekar - NID
- K. Shah - NID